FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer

Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibro...

Descripción completa

Detalles Bibliográficos
Autores principales: Symeonides, Stefan N., Anderton, Stephen M., Serrels, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319091/
https://www.ncbi.nlm.nih.gov/pubmed/28239470
http://dx.doi.org/10.1186/s40425-017-0217-6
_version_ 1782509315507093504
author Symeonides, Stefan N.
Anderton, Stephen M.
Serrels, Alan
author_facet Symeonides, Stefan N.
Anderton, Stephen M.
Serrels, Alan
author_sort Symeonides, Stefan N.
collection PubMed
description Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further supports the use of FAK inhibitors in combination with immunotherapy.
format Online
Article
Text
id pubmed-5319091
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53190912017-02-24 FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer Symeonides, Stefan N. Anderton, Stephen M. Serrels, Alan J Immunother Cancer Commentary Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further supports the use of FAK inhibitors in combination with immunotherapy. BioMed Central 2017-02-21 /pmc/articles/PMC5319091/ /pubmed/28239470 http://dx.doi.org/10.1186/s40425-017-0217-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Symeonides, Stefan N.
Anderton, Stephen M.
Serrels, Alan
FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
title FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
title_full FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
title_fullStr FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
title_full_unstemmed FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
title_short FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer
title_sort fak-inhibition opens the door to checkpoint immunotherapy in pancreatic cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319091/
https://www.ncbi.nlm.nih.gov/pubmed/28239470
http://dx.doi.org/10.1186/s40425-017-0217-6
work_keys_str_mv AT symeonidesstefann fakinhibitionopensthedoortocheckpointimmunotherapyinpancreaticcancer
AT andertonstephenm fakinhibitionopensthedoortocheckpointimmunotherapyinpancreaticcancer
AT serrelsalan fakinhibitionopensthedoortocheckpointimmunotherapyinpancreaticcancer

Ejemplares similares